Elinzanetant (Lynkuet)
Hormones · NK1/NK3 dual receptor antagonist (non-hormonal)
Tier A-
What this is
Bayer; brand Lynkuet. The NK1 addition provides a sleep/mood advantage that may make elinzanetant the preferred non-hormonal VMS therapy where available — especially since liver monitoring isn't required (vs fezolinetant). Also being studied for endocrine-therapy-induced hot flashes in breast cancer survivors.
Mechanism
Dual neurokinin 1 + neurokinin 3 receptor antagonist; the NK1 component additionally improves sleep and mood vs fezolinetant's NK3-only mechanism; same hypothalamic KNDy-circuit normalization for VMS
Dose & route
120 mg PO once daily
Citations
- https://doi.org/10.1007/s40264-026-01663-9
- https://doi.org/10.1007/s40265-025-02231-8
- https://pubmed.ncbi.nlm.nih.gov/41028653/
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.